<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934/1/
NEUROGEN CORPORATION
--------------------
(Name of Issuer)
Common Stock
------------
(Title of Class of Securities)
64124E106
---------
(CUSIP Number)
Hope Flack
BVF Inc.
c/o Grosvenor Capital Management, L.P.
333 West Wacker Drive, Suite 1600
Chicago, Illinois 60606
(312) 263-7777
--------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
January 22, 1997
----------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Check the following box if a fee is being paid with the statement [X]. (A
fee is not required only if the reporting person: (1) has a previous statement
on file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom
copies are to be sent.
(Continued on following pages)
(Page 1 of 8 Pages)
- ----------------------
/1/ The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 64124E106 13D PAGE 2 OF 8 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Biotechnology Value Fund, L.P.
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [X]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS
4
N/A
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
5 [ ]
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
Delaware
- ------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF 0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
441,620
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING 0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
441,620
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
441,620
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
12
[ ]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
13
3.1%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14
PN
- ------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 64124E106 13D PAGE 3 OF 8 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
BV Partners L.P.
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [X]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS
4
N/A
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
5 [ ]
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
Delaware
- ------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF 0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
831,006
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING 0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
831,006
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
831,006
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
12
[ ]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
13
5.8%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14
PN
- ------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 64124E106 13D PAGE 4 OF 8 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
BVF Inc.
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [X]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS
4
N/A
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
5 [ ]
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
Delaware
- ------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF 0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
831,006
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING 0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
831,006
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
831,006
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
12
[ ]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
13
5.8%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14
IA, CO
- ------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 64124E106 13D PAGE 5 OF 8 PAGES
- ----------------------- ---------------------
ITEM 1. SECURITY AND ISSUER.
This Statement on Schedule 13D (this "Statement") relates to the Common
Stock, par value $.025 per share (the "Stock"), of Neurogen Corporation
("Neurogen"). The principle executive office of Neurogen is located at 35
Northeast Industrial Road, Branford, Connecticut 06405.
ITEM 2. IDENTITY AND BACKGROUND.
The persons filing this Statement, the persons enumerated in Instruction C
of Schedule 13D and, where applicable, their respective places of organization,
general partners, directors, executive officers and controlling persons, and
certain information regarding each of them, are as follows:
(a) Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF,
L.P."), BVF Partners L.P., a Delaware limited partnership ("Partners"), BVF
Inc., a Delaware corporation ("BVF Inc."), and Mark N. Lampert, an individual
("Lampert")(collectively, the "Reporting Persons").
(b) The business address of BVF, L.P. and Partners is 333 West Wacker
Drive, Suite 1600, Chicago, Illinois 60606. The business address of BVF Inc.
and Lampert is One Sansome Street, 39th Floor, San Francisco, California 94104.
(c) Partners is the general partner of BVF, L.P., which is an investment
limited partnership. BVF Inc. is an investment adviser to and general partner of
Partners. Lampert is the sole shareholder, sole director and an officer of BVF
Inc.
(d) During the last five years, none of such persons has been convicted in
a criminal proceeding (excluding traffic violations and similar misdemeanors).
(e) During the last five years, none of such persons was a party to a civil
proceeding of a judicial or administrative body of competent jurisdiction and as
a result of such proceeding was or is subject to a judgment, decree or final
order enjoining future violations of, or prohibiting or mandating activities
subject to, federal or state securities laws or finding any violation with
respect to such laws.
(f) Lampert is a citizen of the United States of America.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
Partners, in its capacity as general partner of BVF, L.P., has purchased on
behalf of such
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 64124E106 13D PAGE 6 OF 8 PAGES
- ----------------------- ---------------------
limited partnership shares of the Stock utilizing funds provided by BVF, L.P.
from its working capital pursuant to the terms of its limited partnership
agreement with Partners. Partners, in its capacity as investment manager with
respect to managed accounts, has purchased on behalf of such managed accounts
shares of the Stock utilizing funds under management by Partners pursuant to an
investment management agreement between Partners and such managed account.
ITEM 4. PURPOSE OF TRANSACTION.
The sole purpose of the acquisitions and dispositions of the Stock reported
herein is and was for investment. The Reporting Persons did not at the time of
such acquisitions and dispositions of the Stock, and do not presently, have any
plan to acquire Neurogen. The Reporting Persons may acquire or dispose of
additional shares of the Stock from time to time.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) BVFLP beneficially owns 441,620 shares of the Stock, Partners
beneficially owns 831,006 shares of the Stock, and BVF Inc. beneficially owns
831,006 shares of the Stock, approximately 3.1%, 5.8% and 5.8%, respectively, of
the aggregate number of shares outstanding as of March 5, 1997.
(b) BVFLP shares voting and dispositive power over the 441,620 shares of
the Stock it beneficially owns with Partners. Partners and BVF Inc. share voting
and dispositive power over the 831,006 shares of the Stock they beneficially own
with, in addition to BVFLP, the managed accounts on whose behalf Partners, as
investment manager, purchased such shares. The managed accounts on whose behalf
Partners owns shares of the Stock are Investment 10 L.L.C., an Illinois limited
liability company ("ILL10"), Palamundo, L.D.C., a limited duration company
organized under the laws of the Cayman Islands ("Palamundo"), ZPG Securities,
L.L.C., a New York limited liability company ("ZPG") and Biotechnology Value
Fund, Ltd., a Cayman Islands Corporation ("BVF Ltd."). ILL10, Palamundo, ZPG and
BVF Ltd. are collectively referred to herein as the "Accounts." The Accounts
specialize in holding biotechnology stocks for investment purposes and the
business address of each is c/o Grosvenor Capital Management, L.P., 333 West
Wacker Drive, Suite 1600, Chicago, Illinois 60606.
(c) Exhibit B attached hereto contains information as to all transactions
in the Stock by the Reporting Persons during the past 60 days. All such
transactions were made for cash in open market, over-the-counter transactions.
No other transactions in the Stock have been effected by the Reporting Persons
during the past 60 days.
(d) The Accounts are entitled to receive dividends and any sale proceeds
with respect to the Stock in proportion to their respective ownership interests
therein.
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 64124E106 13D PAGE 7 OF 8 PAGES
- ----------------------- ---------------------
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
Partners is the general partner of BVF, L.P. pursuant to a limited
partnership agreement which authorizes Partners, among other things, to invest
the funds of BVF, L.P. in the Stock and to vote and dispose of the Stock.
Pursuant to such limited partnership agreement, Partners is entitled to
allocations based on assets under management and realized and unrealized gains
thereon. Pursuant to investment management agreements with the Accounts,
Partners and BVF Inc. have the authority, among other things, to invest funds of
the Accounts in the Stock and to vote and dispose of the Stock. Pursuant to such
agreements, Partners and BVF Inc. receive fees based on assets under management
and realized and unrealized gains thereon. BVF Inc. is the general partner of
Partners and may be deemed to own beneficially securities over which Partners
exercises voting and dispositive power.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
Exhibit A - Agreement Regarding Joint Filing
Exhibit B - Transactions in the Stock by the Reporting Persons during the
last 60 days.
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 64124E106 13D PAGE 8 OF 8 PAGES
- ----------------------- ---------------------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: March 5, 1997
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
---------------------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-------------------------------------
Mark N. Lampert
President
BVF INC.
By: /s/ MARK N. LAMPERT
-------------------------------------
Mark N. Lampert
President
<PAGE>
EXHIBIT A
AGREEMENT REGARDING JOINT FILING
--------------------------------
The undersigned, Biotechnology Value Fund, L.P., a Delaware limited
partnership, and BVF Partners L.P., a Delaware limited partnership, and BVF
Inc., a Delaware corporation, hereby agree and acknowledge that the Amendment
containing the information required by Schedule 13D, to which this Agreement is
attached as an exhibit, is filed on behalf of each of them. The undersigned
further agree that any further amendments or supplements thereto shall also be
filed on behalf of each of them.
Dated: March 5, 1997
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-------------------------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-----------------------------------------
Mark N. Lampert
President
BVF INC.
By: /s/ MARK N. LAMPERT
-------------------------------------
Mark N. Lampert
President
<PAGE>
EXHIBIT B
TRANSACTIONS IN THE STOCK BY THE REPORTING PERSONS
--------------------------------------------------
DURING THE LAST 60 DAYS
-----------------------
<TABLE>
<CAPTION>
Settlement For the Price Per Type of
---------- ------- --------- -------
Date By Account of Quantity Share Trade Broker
---- -- ---------- -------- ----- ----- ------
<C> <S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------
1/13/97 Partners BVF, L.P. 14,500 22.1370 Sale GROW
- ----------------------------------------------------------------------------------------
1/13/97 Partners ILL10 27,000 22.1370 Sale GROW
- ----------------------------------------------------------------------------------------
1/13/97 Partners Palamundo 5,000 22.1370 Sale GROW
- ----------------------------------------------------------------------------------------
1/13/97 Partners ZPG 3,500 22.1370 Sale GROW
- ----------------------------------------------------------------------------------------
1/15/97 Partners BVF, Ltd. 35,500 21.0625 Purchase GROW
- ----------------------------------------------------------------------------------------
1/15/97 Partners ZPG 5,000 21.0625 Purchase GROW
- ----------------------------------------------------------------------------------------
1/15/97 Partners Palamundo 7,000 21.0625 Purchase GROW
- ----------------------------------------------------------------------------------------
1/15/97 Partners ILL10 10,000 21.0625 Purchase GROW
- ----------------------------------------------------------------------------------------
1/15/97 Partners BVF, L.P. 42,500 21.0625 Purchase GROW
- ----------------------------------------------------------------------------------------
1/22/97 Partners BVF, L.P. 10,000 18.7500 Purchase MIST
- ----------------------------------------------------------------------------------------
1/23/97 Partners BVF, L.P. 10,000 18.6250 Purchase GROW
- ----------------------------------------------------------------------------------------
1/23/97 Partners BVF, L.P. 10,000 18.6875 Purchase MIST
- ----------------------------------------------------------------------------------------
2/10/97 Partners BVF, L.P. 2,000 19.3125 Purchase MIST
- ----------------------------------------------------------------------------------------
2/18/97 Partners BVF, L.P. 1,000 19.3750 Purchase MIST
- ----------------------------------------------------------------------------------------
2/20/97 Partners BVF, L.P. 3,000 19.3750 Purchase MIST
- ----------------------------------------------------------------------------------------
2/24/97 Partners BVF, L.P. 6,000 19.5000 Purchase MIST
- ----------------------------------------------------------------------------------------
2/25/97 Partners BVF, L.P. 4,000 19.5000 Purchase MIST
- ----------------------------------------------------------------------------------------
3/03/97 Partners BVF, L.P. 4,500 18.0420 Purchase GROW
- ----------------------------------------------------------------------------------------
3/03/97 Partners ZPG 3,000 18.0420 Purchase GROW
- ----------------------------------------------------------------------------------------
3/04/97 Partners BVF, Ltd. 4,000 17.8000 Purchase GROW
- ----------------------------------------------------------------------------------------
3/04/97 Partners ZPG 4,000 17.8000 Purchase GROW
- ----------------------------------------------------------------------------------------
3/04/97 Partners BVF, L.P. 42,000 17.8000 Purchase GROW
- ----------------------------------------------------------------------------------------
3/05/97 Partners BVF, L.P. 14,000 17.0150 Purchase GROW
- ----------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
- ----------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
3/05/97 Partners ILL10 5,000 17.0150 Purchase GROW
- ----------------------------------------------------------------------------------------
3/05/97 Partners BVF, Ltd. 5,000 17.0150 Purchase GROW
- ----------------------------------------------------------------------------------------
</TABLE>
MIST = Mr. Stock Inc.
GROW = Pacific Growth Inc.
RSSF = Robertson Stephens & Co.
